CONMED (CNMD) Expected to Post Quarterly Earnings on Wednesday

CONMED (NYSE:CNMD) is projected to announce its Q2 2026 results after the market closes on Wednesday, July 29th. Analysts expect CONMED to announce earnings of $1.10 per share and revenue of $337.5960 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The company had revenue of $317.05 million for the quarter, compared to analyst estimates of $310.64 million. During the same period last year, the firm earned $0.95 earnings per share. The firm’s revenue was down 1.3% on a year-over-year basis. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Trading Up 0.1%

Shares of CNMD stock opened at $42.73 on Monday. CONMED has a 52-week low of $31.44 and a 52-week high of $56.63. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29. The company has a 50-day simple moving average of $36.47 and a two-hundred day simple moving average of $38.39. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 3.16 and a beta of 0.93.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CNMD. Bank of America reiterated an “underperform” rating and set a $40.00 price target on shares of CONMED in a report on Monday, June 29th. Zacks Research downgraded CONMED from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Wells Fargo & Company set a $39.00 price objective on CONMED in a research note on Monday, July 13th. JPMorgan Chase & Co. decreased their target price on CONMED from $43.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, April 30th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $38.80.

Institutional Investors Weigh In On CONMED

Large investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP bought a new stake in CONMED during the third quarter worth about $47,026,000. Marshall Wace LLP bought a new position in shares of CONMED during the 4th quarter valued at about $9,029,000. Dimensional Fund Advisors LP increased its position in shares of CONMED by 19.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,296,776 shares of the company’s stock valued at $60,984,000 after purchasing an additional 214,126 shares during the last quarter. Millennium Management LLC purchased a new position in shares of CONMED during the 3rd quarter valued at about $9,239,000. Finally, Trexquant Investment LP purchased a new position in shares of CONMED during the 4th quarter valued at about $5,522,000.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.